SYK Stock Recent News
SYK LATEST HEADLINES
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich.
xAI Holdings led performance, driven by rapid AI innovation, Grok 3 launch, and the strategic acquisition of X, enhancing data access and integration. Spotify delivered strong results with margin expansion, robust user growth despite price hikes, and record free cash flow, positioning it as a long-term streaming leader. Nvidia, Tesla, and Broadcom detracted due to market skepticism and macro concerns, but we remain confident in their long-term AI-driven growth prospects.
Stryker Corporation (NYSE:SYK ) Bank of America Securities 2025 Global Healthcare Conference May 13, 2025 4:40 PM ET Company Participants Preston Wells - Chief Financial Officer Jason Beach - Vice President, Finance and Investor Relations Conference Call Participants Travis Steed - Bank of America Travis Steed [abrupt start] the Bank of America medical device analyst and continuing our day of Medtech conversations. Next up we've got Stryker Corporation, Preston Wells, newly appointed CFO; and Jason Beach, VP of Finance and IR.
If you read Fundsmith's Owner's Manual, the influence of Warren Buffett on Terry Smith's hedge fund is plainly obvious. Smith references the Oracle of Omaha's wisdom and Berkshire Hathaway's success no fewer than six times in the 17-page document.
I am downgrading Stryker Corporation to a Hold rating with a fair value of $380 per share, despite strong performance and growth prospects. Stryker's Mako spine and shoulder applications are set to launch soon, potentially boosting its orthopedics and spine businesses. Stryker posted robust Q1 results with 10.1% organic revenue growth and 13.6% adjusted EPS growth, driven by strong topline and margin improvements.
Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better.
The Investment Committee kick off the week with their top picks. Don't miss it!
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.